Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7001–7050 of 75461
Robert Wright, the Senior Vice President, Deputy Chief Financial Officer, and Chief Accounting Officer of the Company and the Partnership, will serve in addition as Executive Vice President and Chief Financial Officer of the Partnership, effective April 1, 2025.
On April 1, 2025, Vincent Donargo notified Calumet, Inc. (the “Company”) of his resignation as the Company’s Chief Accounting Officer and principal accounting officer, effective April 15, 2025 (the “Effective Date”).
On the Effective Date, David Lunin will assume the role as the Company’s principal accounting officer, which is in addition to Mr. Lunin’s existing roles as Executive Vice President, Chief Financial Officer and principal financial officer of the Company.
Pierre-Marie De Leener and Mark Tomkins, two members of the Board of Directors (the “Board”) of Trinseo PLC (the “Company”), notified the Company of their decision to retire from the Board and not stand for reelection at the Company’s 2025 annual general meeting of shareholders.
Pierre-Marie De Leener and Mark Tomkins, two members of the Board of Directors (the “Board”) of Trinseo PLC (the “Company”), notified the Company of their decision to retire from the Board and not stand for reelection at the Company’s 2025 annual general meeting of shareholders.
Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.
In addition, directors Karen J. LaRochelle and John Coelho also resigned from the Board on that date, effective immediately.
On April 2, 2025, Howard J. Weisman, chairman of the Board of Directors (the “Board”) of PaxMedica, Inc., a Delaware corporation (the “Company”), tendered his resignation from that role effective immediately.
In addition, directors Karen J. LaRochelle and John Coelho also resigned from the Board on that date, effective immediately.
thereafter, on March 31, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to no later than April 30, 2025
Mr. Bell will be entitled to an annual base salary of $290,000, and to participate in those benefit plans generally available to all employees of the Company.
the Board appointed Carson Heagen, who currently serves as the Company’s Vice President of Operations, to serve as the Company’s Chief Operating Officer, effective immediately upon Mr. Shoun’s resignation as of the Resignation Date.
Paul Shoun, the Co-Founder, President, Chief Operating Officer, and Chairman of the Board of Directors (the “Board”) of Expion360 Inc. (the “Company”), is resigning from his role as Chief Operating Officer.
On April 2, 2025, Karen T. McKee, president of ExxonMobil Product Solutions Company, vice president Exxon Mobil Corporation and a named executive officer of the Corporation, announced her intention to retire effective May 1, 2025.
Russell Fleeger, currently the Chief Financial Officer of the Company's Water Systems Segment, will additionally assume the role of Chief Financial Officer on an interim basis
Jeffery Taylor, Vice President and Chief Financial Officer resigned from his position at the Company effective March 28, 2025
In connection with LP’s internal reorganization, LP will eliminate the position of Executive Vice President, General Manager, OSB, resulting in the termination of Jimmy Mason’s employment effective April 7, 2025.
On April 2, 2025, the Board of Directors (the “Board”) of Louisiana-Pacific Corporation (“LP”) approved the appointment of Jason Ringblom, who currently serves as Executive Vice President, General Manager, Siding, to the newly created office of President, overseeing all manufacturing and commercial operations of LP, effective April 7, 2025.
Michael Gabay, President, Brink’s France, will become Executive Vice President and President, Europe
On March 31, 2025, James K. Parks, Executive Vice President and President, Europe, Middle East, Africa and Asia of The Brink’s Company (the “Company”), notified the Company that he plans to retire on May 1, 2025.
Nader Antar, Executive Vice President and President, Brink’s Global Services, will expand his responsibilities to include the Rest of World segment.
The Board of Directors of V.F. Corporation (the “Company”) has appointed Abhishek Dalmia to the role of Executive Vice President and Chief Operating Officer and principal operating officer, effective as of April 3, 2025.
On March 31, 2025, the Company’s Board of Directors (the “Board”) appointed Alberto Toni to succeed Mr. Secor as the Company’s Chief Financial Officer effective as of the day immediately following the First Quarter 10-Q Filing Date.
On March 31, 2025, the Company’s Board of Directors (the “Board”) appointed Alberto Toni to succeed Mr. Secor as the Company’s Chief Financial Officer effective as of the day immediately following the First Quarter 10-Q Filing Date.
the Board of Directors (the “Board”) appointed Jonathan Baksht to succeed David V. Barry as Executive Vice President and Chief Financial Officer of the Company effective May 5, 2025.
Mr. Barry will no longer serve as an executive officer of the Company, however, he will continue in his role as President, Security and Connected Products.
On March 31, 2025, the Board of Directors of The Hanover Insurance Group, Inc. (the “Company”) appointed Richard W. Lavey, 58, to serve as Executive Vice President and Chief Operating Officer of the Company, effective on that date.
On April 1, 2025 (the “Effective Date”), Stephanie Pugliese informed American Eagle Outfitters, Inc. (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), as of the Effective Date, due to her upcoming appointment as President and Chief Executive Officer of another publicly traded company.
appointed J. Anthony Gallegos, Jr. to the Board to fill the seat vacated by David Bradshaw
On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.
Mr. Yumin Liu, Chief Executive Officer (“CEO”), will step down from his role effective April 30, 2025.
The Board of Directors has appointed Ms. Julia Xu, currently an independent director, as Interim CEO, effective May 1, 2025.
On April 2, 2025, Ms. Christine Pambianchi informed Mobileye Global Inc. (the “Company”) of her resignation from the board of directors (the “Board”), effective April 25, 2025 in connection with her resignation as executive vice president and chief people officer of Intel Corporation, the Company’s controlling shareholder.
Mr. Carrel-Billiard currently serves as the Seller’s Head of Real and Alternative Assets and has been appointed as a Class III director.
Ms. Boyer-Chammard currently serves as the Seller’s Head of Sustainable Transformation and Organization and has been appointed as a Class II director.
The Company announced that Bob Hurst, one of Crestview Partners’ nominees on the Company’s board of directors (the “Board”), retired from the Board effective as of April 1, 2025
On April 3, 2025, the Board of Directors (the “Board”) of Ingersoll Rand Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michelle Swanenburg as a director of the Board, effective April 3, 2025
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of the directors of Nevro (D. Keith Grossman, Michael DeMane, Kirt Karros, Sri Kosaraju, Shawn T. McCormick, Kevin O’Boyle, Karen N. Prange, Susan Siegel, Kevin Thornal and Elizabeth Weatherman) resigned from the Board.
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
each of Daniel Scavilla and Keith Pfeil, the directors of Merger Sub immediately prior to the Effective Time, became the directors of Nevro.
On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.